14-3-3β在人脑星形细胞瘤中的表达及意义

目的探讨14-3-3β在人脑星形细胞瘤中表达与肿瘤病理分级的关系。方法采用免疫组化法检测14-3-3β亚型在80例人脑星形细胞瘤和10例正常脑组织标本中的表达水平。结果在正常脑组织中，14-3-3蛋白6亚型只表达于神经元胞体和突起，在胶质细胞中未见表达。母亚型在人脑星形细胞瘤的表达阳性率及免疫反应评分（IRS）分别为60％、1．86±1．83。Ⅰ～Ⅳ级脑星形细胞瘤中β亚型表达阳性率分别为40％（8／20）、50％（10／20）、70％（14／20）和80％（16／20）。Ⅰ～Ⅳ级脑星形细胞瘤中β亚型IRS分别为0．88．4±0．27、1．15±0．28、2．19±0．37和3．23±0．47。不同恶性级别的脑星形细胞瘤中，14．3-3蛋白β亚型的阳性表达率无显著差异，但其IRS有显著差异（P〈0．05）。结论14-3-3β在人脑星形细胞瘤中高表达，且随着星形细胞瘤病理级别的增高而表达增强，14-3-3蛋白β亚型在脑星形细胞瘤的发生过程中具有重要作用。

Expresion of 14-3-3β and its significance in human astrocytomas

Objective To provide the correlation between the expression of 14-3-3β protein and the pathological grades in astrocytomas. Methods Ten normal brain tissues and eighty cases of astrocytomas were collected in this study. 14-3-3β protein was detected by immunohistochemical avidin-biotin-peroxidase complex method. The relationship between expression of 14-3-3β protein and pathological grades of astrocytomas was analyzed. Results In the normal brain, 14-3-3β immunoreactivity was localized mainly in the neuronal somata and processes, but not seen in glial ceils. The positive expression percentage was 60%（48/80） and immunoreactivity score （IRS） of 14-3-3β in astrocytomas was 1.86 ± 1.83. 14-3-3β immunoreactivity was seen in the majority of astrocytomas [40% （8/20） in grade Ⅰ, 50%（10/20） in grade Ⅱ, 70%（14/20） in grade Ⅲ and 80%（16/20） in grade Ⅳ]. 14-3-3β IRS was 0.88±0.27, 1.15±0. 28, 2. 19±0. 37 and 3. 23±0. 47 in grade Ⅰ to Ⅳ astrocytomas respectively. There were significant difference （P〈0.05） among 14-3-3β IRS in grade Ⅰto Ⅳ astrocytomas, respectively. Conclusion 14-3-3β is overexpressed in astrocytomas and its expression is increased markedly with an increase in the pathologic grade of human astrocytomas. These results indicate that 14-3-3β may play an important role in tumorigenesis of human astrocytomas.